205p 0.0 0.0%
Last Trade - 4:14pm
| Market Cap | ÂŁ366.5m |
| Enterprise Value | ÂŁ451.9m |
| Revenue | ÂŁ42.5m |
| Position in Universe | 660th / 1805 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 1.49 | 14.4 | 17.1 | 58.1 | 180.6 | 202.3 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Amryt Pharma Holdings Limited, formerly Amryt Pharma plc, is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. Its products include AP 101 and AP102. AP101 (Episalvan) is a potential treatment for Epidermolysis Bullosa (EB), and it is in Phase III clinical trials. AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases. It holds a license to sell Lojuxta (lomitapide) for adults, across the European Union (EU) and other territories, including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | December 20, 2004 |
| Public Since | April 27, 2007 |
| No. of Shareholders: | n/a |
| No. of Employees: | 99 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 178,801,593 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Ivybridge House 1 Adam Street, LONDON, WC2N 6LE, United Kingdom |
| Web | https://www.amrytpharma.com/ |
| Phone | +44 20 34155730 |
| Contact | () |
| Auditors | Grant Thornton |
As of 4:14pm, shares in Amryt Pharma Holdings are trading at 205p, giving the company a market capitalisation of ÂŁ366.5m. This share price information is delayed by 15 minutes.
Shares in Amryt Pharma Holdings are currently trading at 205p and the price has moved by 64.66% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Amryt Pharma Holdings price has moved by 79.14% over the past year.
Of the analysts with advisory recommendations for Amryt Pharma Holdings, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Amryt Pharma Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Amryt Pharma Holdings is scheduled to issue upcoming financial results on the following dates:
Amryt Pharma Holdings does not currently pay a dividend.
Amryt Pharma Holdings does not currently pay a dividend.
Amryt Pharma Holdings does not currently pay a dividend.
To buy shares in Amryt Pharma Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Amryt Pharma Holdings are currently trading at 205p, giving the company a market capitalisation of ÂŁ366.5m.
Here are the trading details for Amryt Pharma Holdings:
Based on an overall assessment of its quality, value and momentum, Amryt Pharma Holdings is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Amryt Pharma Holdings are currently priced at 205p. At that level they are trading at 0.196% discount to the analyst consensus target price of 205.40.
Analysts covering Amryt Pharma Holdings currently have a consensus Earnings Per Share (EPS) forecast of -0.0239496994 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amryt Pharma Holdings. Over the past six months, the relative strength of its shares against the market has been -1.87%. At the current price of 205p, shares in Amryt Pharma Holdings are trading at 17.84% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Amryt Pharma Holdings.
Amryt Pharma Holdings's management team is headed by:
Here are the top five shareholders of Amryt Pharma Holdings based on the size of their shareholding:
